Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2312837 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
J Thromb Haemost
March 2025
MAHSC Professor, University of Manchester, Oxford Road, Manchester, United Kingdom.
Monitoring unfractionated heparin (UFH) to ensure effective anticoagulation may be performed using anti-factor Xa activity (anti-Xa) instead of the activated partial thromboplastin time. However, in patients who have been treated with oral factor Xa (FXa) inhibitors (apixaban, rivaroxaban, and edoxaban) while switching to UFH therapy, there is a risk that these oral anti-FXa drugs could interfere with UFH calibrated anti-Xa monitoring. This may lead to inappropriate anticoagulation management.
View Article and Find Full Text PDFTreatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post-hoc analysis of the Hokusai VTE Cancer study.
J Thromb Haemost
March 2025
Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Background: The management of recurrent venous thromboembolism (VTE) despite anticoagulant treatment in patients with cancer is uncertain. To address this, we used data from the Hokusai VTE Cancer trial, which compared edoxaban with dalteparin to treat cancer-associated VTE.
Methods: In this post-hoc analysis, we characterized and evaluated anticoagulant treatment strategies during and after on-treatment recurrent VTE, including the type and dose of anticoagulant.
Readily available and rapid turn-around, bedside assays to measure the effect of the direct oral anticoagulants (DOACs) are not available. This study evaluates a point-of-care (PoC) coagulometer to assess the anticoagulant effects of the DOACs and low molecular weight heparin. Studies were done in fresh spiked blood from healthy volunteers.
View Article and Find Full Text PDFTwo-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF Program.
Clin Cardiol
February 2025
Center for Cardiovascular Research, University of Birmingham and SWBH and UHB NHS Trusts, Birmingham, UK.
Background: Randomized clinical trials demonstrated similar efficacy and improved safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation (AF). Long-term data in routine clinical practice are needed.
Hypothesis: Patients with AF receiving edoxaban at baseline continue to have low annualized effectiveness and safety event rates in the second year of follow-up, with regional variations observed.
Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model.
Atheroscler Plus
March 2025
Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Background: The combination of antiplatelet and antithrombotic drugs increases the risk of bleeding in patients with atrial fibrillation after coronary drug-eluting stent (DES) implantation. However, the appropriateness of direct-acting oral anticoagulant (DOAC) monotherapy at the time of stent implantation remains uncertain. The objective of this study was to evaluate the safety and efficacy of DOAC monotherapy, specifically using factor Xa inhibitors such as edoxaban, in a low-density lipoprotein receptor knockout (LDL-R) miniature pig model of human-like unstable coronary plaques compared to conventional dual-antiplatelet therapy (DAPT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!